DUSA Pharmaceuticals
DUSA Pharmaceuticals is a US-based specialty pharmaceutical company that develops and commercializes a photodynamic therapy system combining LEVULAN KERASTICK (aminolevulinic acid HCl) with BLU-U blue light illumination to treat actinic keratoses, serving dermatologists and other prescribing clinicians.
- Company typePrivate
- Founded1991
- HeadquartersWilmington, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What DUSA Pharmaceuticals does
DUSA Pharmaceuticals is a US-based specialty pharmaceutical company headquartered in Wilmington, founded in 1991, employing 51–100 people, and historically identified by its NASDAQ ticker (NASDAQGM: DUSA). The firm is fully integrated around a single therapeutic modality — photodynamic therapy (PDT) — and serves healthcare professionals, principally dermatologists and other prescribers who treat patients with precancerous skin lesions.
The company's core offering is a two-product drug-device combination: LEVULAN KERASTICK (aminolevulinic acid HCl), a topical prescription photosensitizing agent, and BLU-U, a blue-light illumination device. The products are used sequentially in clinical practice — the LEVULAN solution is applied to affected skin and then activated by BLU-U blue light exposure — and are indicated for the treatment of actinic keratoses. The system is commercialized through a dedicated healthcare-professional portal (levulanhcp.com) and distributed via standard pharmaceutical channels including pharmacies, dermatology clinics, and medical institutions, with pricing determined through healthcare reimbursement and pharmacy dispensing rather than publicly disclosed.
DUSA's revenue model is anchored on prescription drug and device sales into a single primary specialty (dermatology) and a fragmented end-customer base of prescribing clinicians and institutions. Limited visibility is available on funding, M&A, leadership changes, certifications, patents, partnerships, geographic markets served, or expansion activity in the source data, so the company's current commercial momentum and strategic direction cannot be precisely characterized from this evidence base.
DUSA Pharmaceuticals firmographics
Firmographics- Name
- DUSA Pharmaceuticals
- Legal name
- DUSA Pharmaceuticals
- Website
- https://dusapharma.com
- Company type
- Private
- Founded year
- 1991
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- DUSA Pharmaceuticals is a US-based specialty pharmaceutical company that develops and commercializes a photodynamic therapy system combining LEVULAN KERASTICK (aminolevulinic acid HCl) with BLU-U blue light illumination to treat actinic keratoses, serving dermatologists and other prescribing clinicians.
- Ownership category
- akta.pro rank
DUSA Pharmaceuticals industry classification
Industry- Product category
- Dermatology Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Dermocosmetics & Medical-Grade Skincare (CRABAAAF)
Keywords
Where DUSA Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Wilmington
- HQ country
- United States
- HQ region
- North America
Markets served
DUSA Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain
DUSA Pharmaceuticals product offering
Product offeringCore offering
DUSA Pharmaceuticals develops, manufactures, and markets a photodynamic therapy system for the treatment of minimally to moderately thick actinic keratoses of the face or scalp. The offering is a drug-device combination: LEVULAN® KERASTICK® (aminolevulinic acid HCl) topical solution applied to lesions and then activated in-clinic using the BLU-U® blue light device, sold to dermatologists and other prescribers as a regimen.
Product overview
DUSA Pharmaceuticals offers a photodynamic therapy system consisting of two core products used together: LEVULAN® KERASTICK® (aminolevulinic acid HCl), a topical prescription photosensitizing agent, and BLU-U®, a blue light therapy device. These products are indicated for the treatment of actinic keratosis and are used sequentially—the LEVULAN® solution is applied to the affected skin areas and then activated by BLU-U® light illumination.
Differentiator
Problem solved
Functional benefit
Brands
- LEVULAN KERASTICK: Aminolevulinic acid HCl product for photodynamic therapy, used with BLU-U light therapy
Products and services
- LEVULAN® KERASTICK® (aminolevulinic acid HCl) Prescription topical photosensitizing agent containing aminolevulinic acid HCl, applied to actinic keratosis lesions and subsequently activated by BLU-U® blue light illumination for photodynamic therapy of minimally to moderately thick actinic keratoses of the face or scalp; intended for dermatologists and other prescribers.
- BLU-U® Blue Light Photodynamic Therapy Device In-clinic blue light therapy device used by dermatologists and other prescribers to activate topically applied LEVULAN® KERASTICK® during photodynamic therapy for the treatment of minimally to moderately thick actinic keratoses.
Companies that use DUSA Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles1 record
DUSA Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
DUSA Pharmaceuticals partnerships and signals
Strategic signalRecent moves2 records
Expansion highlights1 record
DUSA Pharmaceuticals competitors and assessment
Company assessmentEmerging players
- Mayne Pharma: Mayne Pharma markets branded dermatology and women's-health products including topical acne and AK-related therapies in the US, making it a smaller-scale specialty dermatology comparator.
- Photocure ASA: Photocure commercializes Hexvix/Cysview, a hexyl-aminolevulinate-based imaging agent used in bladder-cancer detection, sharing the same aminolevulinic-acid photosensitizer chemistry family as LEVULAN KERASTICK.
- Photonamic GmbH: Photonamic develops 5-aminolevulinic-acid-based photosensitizers (Alacare, Alapure) and PDT-related medical-device combinations, overlapping on the same drug-device chemistry used by DUSA's LEVULAN platform.
Direct peers
- Dermavant Sciences: Dermavant developed tapinarof (Vtama) and other topical dermatology therapies, including in actinic keratosis; it competes for physician-administrated AK treatment slots and adjacent dermatology indications.
- Biofrontera: Biofrontera markets Ameluz (aminolevulinic acid) gel used with the BF-RhodoLED red-light lamp for PDT of actinic keratoses in the US and EU, making it the most direct competing PDT regimen for the same clinical indication and prescribing audience.
Broad incumbents
- Almirall: Almirall is a European specialty dermatology company with a portfolio including topical treatments for actinic keratosis (e.g., tirbanibulin/SKlice franchise area) and other skin conditions, making it an established comparator in the same prescription dermatology space.
- Galderma: Galderma is a large dermatology-focused pharmaceutical and aesthetics company whose portfolio spans prescription acne, rosacea, and skin-cancer treatments; it is a natural broad incumbent comparator for any prescription dermatology franchise focused on AK and related conditions.
- LEO Pharma: LEO Pharma is a global dermatology specialist with branded products across actinic keratosis, psoriasis, and eczema; it competes for the same dermatology prescriber attention and budget as LEVULAN-based PDT.
- Bausch Health (Ortho Dermatologics): Ortho Dermatologics (Bausch Health) sells branded prescription dermatology products including topical AK therapies (e.g., Solage, Aldara area), competing for the same dermatologist-prescriber mindshare in actinic keratosis.
- Sun Pharma (US dermatology): Sun Pharma operates a broad specialty and generics dermatology portfolio that overlaps with generic and branded AK topicals, providing a comparable prescription dermatology channel and payer footprint.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
DUSA Pharmaceuticals social profiles
Digital presenceDUSA Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
DUSA Pharmaceuticals leadership team
Management profileNumber of profiles
DUSA Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DUSA Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DUSA Pharmaceuticals
What does DUSA Pharmaceuticals do?
DUSA Pharmaceuticals develops, manufactures, and markets a photodynamic therapy system for the treatment of minimally to moderately thick actinic keratoses of the face or scalp. The offering is a drug-device combination: LEVULAN® KERASTICK® (aminolevulinic acid HCl) topical solution applied to lesions and then activated in-clinic using the BLU-U® blue light device, sold to dermatologists and other prescribers as a regimen.
Is DUSA Pharmaceuticals a public or private company?
DUSA Pharmaceuticals is a private company. It is classified as public and is currently operating.
When was DUSA Pharmaceuticals founded?
DUSA Pharmaceuticals was founded in 1991. It employs 51 to 100 people.
Where is DUSA Pharmaceuticals based?
DUSA Pharmaceuticals is headquartered in Wilmington, United States, in the North America region.
Who are DUSA Pharmaceuticals's main competitors?
Emerging players on record are Mayne Pharma, Photocure ASA and Photonamic GmbH. Direct peers are Dermavant Sciences and Biofrontera. Broad incumbents are Almirall, Galderma, LEO Pharma, Bausch Health (Ortho Dermatologics) and Sun Pharma (US dermatology).
Does DUSA Pharmaceuticals have an API?
No public API is recorded for DUSA Pharmaceuticals.
What industry is DUSA Pharmaceuticals in?
DUSA Pharmaceuticals's product category is Dermatology Pharmaceuticals. Its primary akta.pro industry code is CRABAAAF, Dermocosmetics & Medical-Grade Skincare. Its NAICS code is 325412 and its SIC code is 2834.